Myeloid-derived suppressor cells (MDSCs) constitute one of the major populations that potently suppress anti-tumor immune responses and favor tumor growth in tumor microenvironment. However, the mechanism(s) regulating the differentiation and suppressive func- 
Introduction
Myeloid derived suppressor cells (MDSCs) accumulate in large numbers in tumor microenvironment and represent a key player mediating tumor immune tolerance [1] [2] [3] . In mouse, MDSCs are characterized by the simultaneously expression of the myeloid markers Gr-1 and CD11b [4] , which are further subdivided into two subsets including mononuclear cells (MO-MDSCs) with a phenotype of inflammatory monocytes, expressing Ly6C marker (CD11b +
Ly6G
-Ly6C high ) and polymorphonuclear cells (PMN-MDSCs) with a phenotype of immature neutrophils, expressing Ly6G marker (CD11b + Ly6G + Ly6C low ) [3, 5] . In human, the phenotype of MDSCs are less well defined, but are generally regarded as CD11b + CD14 -CD33 + cells or Lin -HLA -DR -CD33 + cells [6] . Two main subpopulations of MDSCs in patients have been recently also identified as CD14 + monocytes and CD15 + neutrophils MDSCs [7] . These MDSCs may suppress immune responses by producing reactive oxygen species (ROS), H 2 O 2 , NO-and arginase. Studies have shown that tumor associated factors such as GM-CSF, M-CSF, VEGF, stem cell factor (SCF), TNFα, IL-6, IFNγ, IL-1β, IL-4 and prostaglandin E2 (PGE2) can promote generation of MDSCs [8] [9] [10] [11] [12] . However, the mechanism controlling their differentiation and function in tumor environment is still not completely clear. Two-signal models are proposed to be responsible for differentiation and suppressive function of MDSCs [13] . One signaling pathway is mainly for MDSC expansion and the other for MDSC activation. Tumor-derived cytokines, such as GM-CSF, M-CSF, G-CSF, IL-6 and VEGF, initiate the first kind of signaling pathways that converge on activation of STAT3 and STAT5. Because of the importance of these transcription factors on cell differentiation and proliferation, signals to them naturally prevent normal myeloid development and promote the expansion of immature myeloid cells. STAT3 regulates transcription of anti-apoptotic or proproliferative factors including BCL-XL, survivin, cyclin D1 and c-myc that are involved in myeloid cell expansion [1, 14] . Activation of STAT3 also upregulates pro-inflammatory proteins S100A8, S100A9 and NADPH oxidase (Nox2) complex, which play a role in the differentiation and suppressive function of MDSCs [15, 16] . Pro-inflammatory molecules such as IFNγ, IL-1β, IL-4, PGE2 and LPS which may induce activation of STAT1, STAT6, PI3K/Akt and NF-κB, are important factors constituting signals start MDSC activation. Notably, PI3K/Akt pathway is also critical for the generation of tumor-expanded MDSCs [17] . A significantly high level of phosphorylated Akt may be detected in tumor-expanded MDSCs and increased Akt activity results in subsequent activation of NF-κB and mTOR, two players in controlling MDSC function [18] . Meanwhile, activation of Akt prolongs the lifespan of MDSCs by regulating the intrinsic apoptotic/survival signal [18] . microRNAs (miRNAs) form a large family of small non-coding RNAs that have emerged as key post-transcriptional regulators of gene expression in mammals [19] . So far, more than 100 different miRNAs have been found to be expressed in immune cells; they are directly implicated in molecular pathways involved in immune response in tumor environment [20] . Indeed, our previous studies [21] [22] [23] have found some miRNAs such as miR-223, miR-22, miR-503, miR-17-5p and miR-20a could regulate intracellular signal pathways to affect the differentiation and function of MDSCs. Here we show that miR-200c, whose genomic locus is located in fragile regions within two chromosomal clusters, including miR-200c-141 cluster and miR200b-200a-429 cluster, strongly promotes the suppressive potential of MDSCs via targeting PTEN and FOG2, leading to subsequent STAT3 and PI3K/Akt activation. Meanwhile, we also show that GM-CSF is a main factor in inducing miR-200c expression in tumor environment. In the immune therapy against tumor, miR-200c inhibitor strongly reduces the suppressive potential of MDSCs and retards tumor growth. These results offer a new method for improving anti-tumor responses.
Materials and Methods

Mice
C57BL/6 and BALB/c mice (male, 4-8 weeks old) were obtained from Beijing Animal Center and maintained under specific pathogen-free conditions. Murine melanoma (B16), lung carcinoma (Lewis), ovarian carcinoma (1D8), colon carcinoma (CT26) and 4T1 breast tumor cell lines were obtained from American Type Culture Collection (ATCC). B16 melanoma, Lewis lung cancer, 1D8 ovarian cancer and CT-26 colon tumor were respectively established in C57BL/6 mice and in BALB/c mice by s.c inoculation of 5-10×10 5 tumor cells. To generate tumor cell conditioned medium (TCCM), sub-confluent tumor cells were kept in medium with serum concentration (2%) for 48 h., and then TCCM was collected, aliquoted, and kept at -80°C until used. The animal experiments were performed in accordance with institutional guidelines and the study was approved by the ethics committee of Nankai University.
Reagents
RPMI1640, DMEM, fetal bovine serum (FBS) and antibiotics were obtained from HyClone.
Recombinant murine GM-CSF, IL-6, TNFα and IL-4 were purchased from Peprotech. PGE2 and 2-ME (2-Mercaptoethanol) were from Sigma. The following Abs were used, including PE-, or FITC-conjugated anti-Gr-1 (RB6-8C5), anti-CD11b (M1/70), anti-Ly6G (1A8), anti-Ly6C (AL21), anti-CD80 (16-10A1), anti-CD86 (GL1), anti-CD40 (3/23), anti-CD11c (N418), anti-PD-1 (J43), anti-B7-H1 (MIH1), anti-CD4 (L3T4), anti-CD8a (Ly-2) and isotype control Abs, which were obtained from BD Biosciences. Purified anti-GM-CSF Ab (MP1-22E9) was purchased from Biolegend.
Flow cytometric analysis
Single cell suspensions were stained with the indicated FITC-or PE-labeled antibodies at 4°C for 25 min in phosphate buffer saline (PBS) with 1% fetal calf serum (FCS). Cells were then washed twice, resuspended in PBS with 1% paraformadehyde and 1% FCS, and kept at 4°C prior to flow cytometric analysis. Cells were analyzed on a FACScan flow cytometer (BD Biosciences).
In vitro generation of MDSCs
BM cells were obtained as described previously [24] . Briefly, BM cells were collected by removing the femurs of mice, and flushing out the marrow in RPMI1640 medium. The red blood cells were lysed with ammonium chloride buffer. For induction of MDSCs, 2 × 10 6 BM cells were plated into 6-well plates in medium. The medium was supplemented with different cytokines combinations, including GM-CSF (40 ng/ml) alone, GM-CSF (40 ng/ml) with IL-6 (40 ng/ml), TNFα (40 ng/ml), IL-4 (40 ng/ml) and PEG2 (1.0 μg/ml) or 25% v/v TCCM in the presence of 20 μM 2-ME, 10% FCS, and 1% penicillin and streptomycin.
MDSCs isolated from B16, CT-26 and Lewis tumor
CD11b+Gr-1+MDSCs were isolated by biotinylated CD11b and Gr-1 mAbs together with anti-biotin-coated magnetic microbeads according to the manufacturer's protocol (Miltenyi Biotec.). Purity of cell populations reached more than 90%.
RNA isolation and real-time quantitative PCR
Total RNA was isolated using Trizol Reagent (Invitrogen). Real-time quantitative RT-PCR (qRT-PCR) was performed using SYBR RT-PCR kits (Takara) and CFX96 Real-Time PCR Detection System (Bio-Rad). The relative expression level of gene and miRNAs was normalized to that of endogenous control GAPDH mRNA and U6 small RNA, respectively. Fold changes were calculated using the 2 -ΔΔCt method. PCR reactions were conducted in triplicate for each sample. The primers for detecting all the genes and miRNAs were described in Table A in S1 File.
Transfection
The cells were cultured on 6-well plate and transfected in the following day. For miRNA mimics, inhibitors, siRNAs, and control oligonucleotides (oligoes, Guangzhou RiboBio), cells were transfected with the indicated oligoes (100 nM) using the Hiperfect Transfection Reagent (Qiagen) according to the manufacturers' instructions.
Luciferase reporter assay
3'-UTR reporter plasmids were constructed by cloning the PTEN 3'-UTR sequence (Fig A in S1 File) into downsteam of firefly luciferase cassette in pSiCHECK-2 vector (Promega). HEK293T Cells were cultured in a 24-well plate at a density of 1 × 10 5 cells/well before transfection, and then cells were cotransfected with the WT-3'-UTR reporter plasmids, mutated-3'-UTR reporter plasmids, control plasmids (Promega) respectively, and the indicated miRNAs using Lipofectamine reagent (Invitrogen) according to the manufacturers' recommendations. Renilla and firefly luciferase activities were measured 24 h after transfection using the DualLuciferase Reporter Assay System (Promega). Renilla luciferase was normalized according to firefly luciferase activity.
Arginase activity assay
Arginase activity was measured in cell lysates according to the reported protocol. Briefly, cells were lysed for 30 min with 100 μl of 0.1% Triton X-100 at 4°C. Following lysis, 100 μl of 25 mM Tris-HCl and 10 μl of 10 mM MnCl 2 were added and the mixture was heated for 10 min at 56°C. Subsequently, the lysates were incubated with 100 μl of 0.5M L-arginine (pH 9.7) at 37°C for 120 min. The reaction was stopped with 900 μl of H 2 SO 4 (96%)/H3PO4 (85%)/H 2 O (1:3:7). Urea concentration was measured by absorbance at 540 nm after addition of 40 μl of 9% α-isonitrosopropiophenone, followed by heating at 95°C for 30 min. A standard curve was generated by serial dilution of 120 mg/ml urea. Arginase activity (Unit) was defined by the amount enzyme that catalyzes the formation of 1ug of urea per minute.
Nitric oxide production
Nitric oxide in culture supernatant was assayed using Griess Reagent System. Equal volumes of supernatant (50 μl) and sulfanilamide solution (1% sulfanilamide in 5% phosphoric acid) were incubated at room temperature (RT) for 5-10 min, followed by addition of 50 ul of NED solution (0.1% N-1-napthylethylenediamine dihydrochloride). After incubation for 10 min at RT, absorbance at 550 nm was measured. Nitrite concentrations were quantified by comparing the absorbance values to a standard curve generated by serial dilution of 100 uM sodium nitrite.
H 2 O 2 production
Production of H 2 O 2 was evaluated using Amplex Red Hydrogen Peroxide/ Peroxidase Assay Kit (Invitrogen). Briefly, 1×10 4 cells were resuspended in Hanks Balanced Salt Solution. After addition of PMA (30 ng/ml), the absorbance at 560 nm was measured using a microplate reader at 37°C. Absorbance values for the test samples were normalized to a standard curve generated by serial dilutions of 10 mM H 2 O 2 .
Western blotting
Cell lysates were denatured and subjected to SDS-PAGE, and then were transferred to PVDF membranes. The membranes were incubated with the primary Abs, followed by hybridization with the secondary HRP-conjugated Abs. Detection was performed using an enhanced chemiluminescence assay with Lumi-Glo reagents (Millipore). Anti-ARG1,-iNOS,-PTEN and-FOG2 antibodies were obtained from GeneTex. Anti-S100A8 and-S100A9 antibodies were from Abcam. Antibodies for STAT3, Akt, NF-κB P65, β-actin and phosphorylated STAT3, Akt, NF-κB p65 were purchased from Santa Cruz Biotechnology.
Proliferation assay
CD4 + or CD8 + T cells were isolated from splenocytes by biotinylated CD4 and CD8 mAbs together with anti-biotin-coated magnetic microbeads by using Miltenyi Biotec kits and LS columns, and then were resuspended in pre-warmed (37°C) PBS/0.1% FCS containing CFSE (5 uM), and incubated 5 min at 37°C. The reaction was quenched with ice-cold culture media and incubated 10 min on ice. The cells were washed three times and harvested for further analysis. For T cell suppression assay, CFDA-SE labeled CD4 + or CD8 + T cells from splenocytes were seeded in triplicates in 96-well round bottom plates pre-coating with anti-CD3ε antibody (BD Biosciences). CD4 + or CD8 + T cells (1×10 6 /well) were cultured in the presence of increasing MDSCs. CFDA-SE dilution in T cells was analyzed by flow cytometry after three days.
In vivo MDSC suppressive experiments
Effects of tumor-associated miRNAs on suppressive potential of MDSC was assessed according to the previously reported protocol [25] . Mice bearing CT-26 tumors were randomly divided into several experimental groups (six mice per group) and treated via intratumoral injection with 2 × 10 6 pretreated bone marrow derived MDSCs (BM-MDSCs) on days +5, +12, +19 after the inoculation of CT-26 tumor cells. MDSCs were transfected with miR-200c mimics, miR200c inhibitors, FOG2 siRNAs (CTGGAGCAATAAAGAAGACAA) and PTEN siRNAs (GAAGTAAGGACCAGAGACA) or control oligoes (Guangzhou Ribobio, China). Tumor measurements were conducted by assessing the largest diameter and its perpendicular length with a caliper. The tumor size index was the average of these diameters. Mice were sacrificed on day 28.
CD3-ζ Chain staining
For CD3-z Chain staining, T cell surface marker (CD4 and CD8) staining were performed prior to fixation and then cells were washed with PBS twice, followed by fixed with 1% paraformaldehyde in PBS for 15 min, permeabilized with 0.1% Triton X-100 for 10 min, and then washed in PBS. The fixed and permeabilized cells were incubated in 2% BSA/PBS for 30 min to block nonspecific binding. After washing, the cells were incubated with anti-CD3-z mAb for 1hr. All steps were performed at 4°C. Cells were analyzed on a FACScan flow cytometer.
ELISA
ELISA for mouse GM-CSF was performed by using ELISA kit (Beijing 4A Biotech) following manufacturer's instructions. The ODs of each samples were measured at 450nm using a SpectraMax 190 ELISA plate reader. GM-CSF levels were quantitated from three titrations using standard curves and expressed in picograms per milliliter.
Statistical analysis
Student's t-test was used to determine significance. A 95% confidence interval was considered significant and was defined as P < 0.05. Ã p < 0.05, ÃÃ p < 0.01.
Results
miR-200c is highly expressed in tumor-associated MDSCs
We (Fig 1C and 1D) . Furthermore, TCCM induced miR-200c expression was dose-dependent ( Fig 1E) . Thus, tumor-associated factors contributed to miR-200c upregulation, suggesting that miR-200c may be involved in the differentiation and suppressive function of tumor associated MDSCs.
GM-CSF is a main inducer of miR-200c in tumor associated MDSCs
The data from both in vivo tumor models and in vitro induction suggest that tumor-associated factors contribute to miR-200c upregulation in MDSCs. However, it was still unclear which kind(s) of factor(s) in tumor environment is an inducer of miR-200c. To identify this, we first analyzed the expression of miR-200c in in vitro generated MDSCs from different combinations of tumor-derived factors including GM-CSF alone, GM-CSF with IL-6, GM-CSF with TNFα and GM-CSF with IL-4 plus PGE2 according to the protocols previously described [16, 27, 28] (Fig 2A) . We found that miR-200c expression was higher in all MDSCs from different combinations of cytokines than that in untreated BMCs. As shown in Fig 2B, 2-3 fold high levels of miR-200c could be detected after culturing for 2 days. Continuing culture could continuously increase the expression of miR-200c to reach 5-6 folds as compared to control group. However, addition of TNFα, IL-6 or IL-4 and PEG2 was not able to promote the expression of miR-200c as compared to GM-CSF alone. In contrast, these factors reduced the expression of GM-CSFmediated miR-200c expression in some degrees (Fig 2B) , indicating that GM-CSF might be a main factor for the expression of miR-200c in tumor environment. To prove this, we investigated the effect of each tumor-derived factor on miR-200c expression respectively. Indeed, while cells were treated with IL-6, TNFα, TGFβ or PGE2, miR-200c expression did not show any significant change (Fig 2C) . However, significant upregulation of miR-200c could be detected in GM-CSF-mediated MDSCs, and further this upregulation was dose-dependent ( Fig  2D) . Importantly, CT-26, 4T1 and 1D8 tumor cells could produce GM-CSF (Fig 2E) , consistent with other findings [29, 30] . Furthermore, addition of anti-GM-CSF mAb into culture also partly inhibited the expression of miR-200c (Fig 2F) . Taken together, these results suggest that the tumor-derived factor GM-CSF contributes to the upregulation of MDSC miR-200c in tumor environment.
miR-200c enhances immune suppressive activity and differentiation of MDSCs
Next, we addressed the effect of miR-200c on the differentiation and suppressive function of tumor associated MDSCs. It had been well-known that immunosuppression of tumor (Fig 3A-3C) . Meanwhile, miR- 
MiR-200c Promotes MDSC Function
200c also enhanced arginase activity in MDSCs (Fig 3D) . In contrast, miR-200c inhibitors not only reduced the level of ROS, H 2 O 2 and NO-but also decreased the arginase activity (Fig 3A-3D) . These molecules play a critical role in the suppression of T cell activation and proliferation, such as that ROS causes the loss of the T cell receptor (TCR) CD3z-chain [28, 31, 32] and that arginase 1 affects CD3z chain expression and inhibits TCR-mediated T cell responses [33] . Thus, we further tested the effect of miR-200c mimics loaded MDSCs on T cell activation. CD4 + T or CD8 + T cells were sorted from spleen, labeled by CFSE and stimulated with anti-CD3ε antibody, and then cocultured with differently modified MDSCs. As shown in Fig 3E, miR-200c mimics treated MDSCs showed remarkable suppression on T cell proliferation with a decrease in the percentage of proliferating cells; whereas miR-200c inhibitors alleviated the suppressive function of MDSCs (Fig 3E) . (Fig 4A) . Importantly, the mutation in the putative miR-200c binding sites abolished the repression by miR-200c, demonstrating that miR-200c could specifically target their binding sites in the 3'UTR of PTEN. The protein levels of PTEN were also significantly down-regulated by miR-200c mimics (Fig 4B) . Supporting above finding, anti-miR-200c also upregulated expression of PTEN (Fig 4B) . To further determine that PTEN may be acted as targets of miR-200c, we further investigated the expression of miR-200c and PTEN in BM cells after exposed to TCCM. We found that miR200c and PTEN expression levels exhibited a negative correlation. While miR-200c expression was increased gradually (Fig 4C) , PTEN expression was decreased progressively at both mRNA and protein levels (Fig 4C and 4E) . Meanwhile, we also found that miR-200c down-regulated the expression of FOG2 in both transcriptional and protein levels ( Fig 4B, 4C and 4E ). Importantly, miR-200c inhibitors abolished the suppression of miR-200C on PTEN and FOG2 in the presence of TCCM (Fig 4D) . Taken together, these data demonstrate that miR-200c targets and reduces the levels of PTEN and FOG2 in MDSCs. We next addressed whether miR200c mediated suppressive function in MDSCs was caused from PTEN and FOG2. Indeed, silencing PTEN or FOG2 using PTEN or FOG2 specific siRNAs could increase production of ROS, H 2 O 2 and NO (Fig 5A-5C ) and meanwhile, also enhanced the arginase activity (Fig 5D) . Thus miR-200c could regulate differentiation and suppressive function of MDSCs by targeting PTEN and FOG2.
miR-200c is involved in activation of PI3K/Akt and STAT3 in MDSCs
It has been well known that the NF-κB, STAT3 and PI3K/Akt signal pathways play a critical role in inducing the differentiation and suppressive function of MDSCs [1, 34] . Since both PTEN and FOG2 are regarded as important regulators of these signaling pathways [25, 34] , we next analyzed the effects of miR-200c on the activity of Akt, NF-κB, and STAT3 in MDSCs. As shown in Fig 6A, transfection of miR-200c mimics dramatically enhanced the phosphorylation levels of Akt and STAT3; whereas miR-200c inhibitors reduced the activation of Akt and STAT3. Meanwhile, we also found that miR-200c could promote the phosphorylation of NF-κB subunit p65 (Fig 6A) , consistent with the previous data that PTEN expression is inversely correlated with the phosphorylation levels of NF-κB [18] .
Next, we analyzed the expression of MDSC associated genes such as ARG1, iNOS, S100A8 and S100A9, which may be regulated by Akt, NF-κB, and STAT3 signaling pathway [1, 34] . 
MiR-200c Promotes MDSC Function
Tumor associated MDSCs were isolated from the spleens in Lewis lung carcinoma and B16 melanoma loaded mice. As shown in Fig 6B, higher levels of ARG1, iNOS, S100A8 and S100A9 in CD11b + Gr-1 + cells from Lewis-and B16-tumor bearing mice could be detected as compared to the counterparts from tumor-free mice. For in vitro GM-CSF and IL-6 induced MDSCs, miR-200c also dramatically increased the levels of ARG1, iNOS, S100A8 and S100A9 mRNAs (Fig 6C) . Notably, there was not a significant change in the expression of STAT3, indicating that miR-200c was not involved in regulating its expression. These effects were further confirmed at the protein level (Fig 6D) . Taken (Fig 7C) . Since the downregulation of CD3z chain expression in T cells from the spleens of mice bearing tumor are often related to tumor immune suppression [33] , we also evaluated the CD3z chain expression in T cells from the spleens of mice bearing CT-26 colon carcinoma. The levels of CD3z expression in CD4+ and CD8+ T cells was lower (Fig 7D and Fig D in S1 File) . Similar results could be found in mice bearing tumor after inoculation with PTEN or FOG2 siRNA transfected MDSCs (Fig 7D and Fig D in S1  File) . Thus, miR-200c indeed improves the suppressive function and differentiation of MDSCs.
Discussion
In this study, we demonstrate that miR-200c expressed in myeloid cells can regulate the suppressive function and differentiation of MDSCs by targeting PTEN and FOG2 expression. We have also found that myeloid cells associated miR-200c can be upregulated by tumor associated factor GM-CSF. These results may be used as a basis to improve anti-tumor immunotherapy.
MDSCs play a central role in tumor-mediated immune suppressive network during cancer progression. There is a dynamic interplay between lineage-specific miRNAs and intracellular signal pathways in the development and differentiation of myeloid lineage. The dysregulated miRNAs expression may result in an abnormal differentiation and accumulation of immature myeloid cells. Indeed, several miRNAs contribute to the expansion and suppressive function of MDSCs under pathophysiological conditions such as miR-155 [35] , miR-21 [35] , miR-142-3p [36] , miR-494 [18, 22] , miR-17-5p [22] and miR-20a [22] . Furthermore, these miRNAs also affect tumor growth by interrupting the differentiation and function of MDSCs [22] . We found that miR-200c also positively regulates MDSC differentiation and function. MiR-200c inhibitors may alleviate the immune suppressive potential of MDSCs to retard tumor growth. Thus, these miRNAs can serve as potential treatment targets of anti-tumor immune therapy.
MiRNAs in MDSCs mainly focus on PI3K/Akt and STAT3 signal pathways [1, 34] . STAT3 is a main transcriptional factor in the process of MDSC differentiation with the ability to drive CEBPβ, BCL-XL, c-myc, survivin and cyclin D1 expression [1, 34] . PI3K/Akt signaling pathway is also critical in the proliferation and survival of MDSCs through regulating the expression of transcription factors and genes [1, 34] . Notably, PI3K and STAT3 signal pathway may form a complex signaling network with mTOR/PTEN signals in regulating the differentiation and function of MDSC [37] . PTEN, a protein/lipid phosphatase, is the most important negative regulator of PI3K/Akt signaling pathway [25] . While FOG2 is found to bind to a regulatory subunit of PI3K, It is also acted a negative modulator of the PI3K/Akt pathway [34] . Studies show that some MDSC associated miRNAs could interrupt the activity of these signal pathways such as that miR-494 promotes the accumulation and function of tumor-expanded MDSC via targeting PTEN, which results in the subsequent activation of the Akt, NF-κB, and mTOR pathways. MiR-155 and miR-21 can promote STAT3 activation via targeting SHIP-1 and PTEN, respectively, synergistically leading to MDSC expansion [1, 34] . Our previous studies also show that miR-17-5p and miR-20a may alleviate MDSC suppressive potential by reducing STAT3 expression [22] . miR-200c is found to regulate the expression of PTEN and FOG2 to enhance the suppressive potential and promote the generation of MDSCs.
We found that GM-CSF is an effective inducer of miR-200c in tumor environment. GM-CSF is generally known as a cytokine capable of inducing the generation of granulocytes, monocytes and dendritic cells from BM precursors. However, it can also promote the formation of immune suppression within the tumor microenvironment. Under steady state, GM-CSF keeps at a low concentration in circulation and augments the systemic anti-tumor immune response. Meanwhile, during tumor initiation and progression, a high level of GM-CSF is necessary to drive the development of CD11b + Gr-1 + cells that lead to immune suppression [38, 39] . Studies show that tumor-derived GM-CSF may be as one of the key factors in the generation of MDSCs both in vivo and in vitro [40, 41] . There is a direct correlation between secretion of GM-CSF in patients with head and neck cancers and presence of circulating immune suppressive GM progenitor cells [42] . Tumor cell-derived GM-CSF is also suggested to drive the accumulation of suppressive CD11b + Gr-1 + myeloid cells in pancreatic cancers [30, 43] . Its blockade and knockdown inhibits the recruitment of CD11b + Gr-1 + cells to the tumor microenvironment and arrest tumor development [30] .
In conclusion, our data suggest a working model of miR-200c in regulating the activation of tumor-expanded MDSCs (Fig 7E) . Tumor-derived GM-CSF induces the expression of miR200c, which targets and negatively regulates FOG2 and PTEN expression. Down-regulation of FOG2 and PTEN promotes the activation of Akt and its downstream signaling pathways to enhance the expansion and immune suppressive potential of MDSCs.
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